Fig. 3.

Levels of intra-platelet VEGF and PF4 “normalize” with exposure to therapy. VEGF and PF4 were identified as differentially expressed between platelets of normal subjects and patients with breast cancer, and demonstrated dynamic change with exposure to therapy. All measurements were repeated on 2 separate occasions, and the graph represents the mean of the two measurements ± SEM. At baseline, the levels of VEGF (Fig. 3a) and PF4 (Fig. 3b) were notably higher in platelets of patients with breast cancer than in those of normal controls. With each subsequent cycle, the levels of both of these proteins “normalized,” and by the third cycle VEGF closely approached levels in platelets of normal healthy subjects